GlassScriptPhysician profile
Andrew Doughan
NPI 1386843852
$7,337.75
in general payments reported to CMS, 2019-2025
30 companies · $522 in 2025
The $522 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,003 · 2020: $187 · 2021: $789 · 2022: $549 · 2023: $1,061 · 2024: $3,227 · 2025: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,710 · Consulting Fee: $2,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,710.30 |
| Consulting Fee | $2,100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $3,711.09 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| E.R. Squibb & Sons, L.L.C. | $537.48 | 2019-2025 | Camzyos, Eliquis |
| United Therapeutics Corporation | $368.06 | 2019-2024 | Tyvaso |
| Penumbra, INC. | $298.80 | 2024 | Indigo System |
| Heartflow, INC. | $265.77 | 2022-2023 | Ffrct |
| Novartis Pharmaceuticals Corporation | $264.80 | 2019-2025 | |
| Pfizer INC. | $258.52 | 2019-2025 | |
| Abbott Laboratories | $214.48 | 2021-2024 | Mitraclip |
| Bayer Healthcare Pharmaceuticals INC. | $171.40 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $158.66 | 2019-2024 | Wainua, Farxiga |
| Siemens Medical Solutions USA, INC. | $146.94 | 2021 | |
| Amgen INC. | $141.51 | 2019 | |
| Merck Sharp & Dohme LLC | $139.98 | 2024-2025 | Winrevair |
| Astellas Pharma US INC | $99.99 | 2019 | |
| Alnylam Pharmaceuticals INC. | $90.79 | 2022-2025 | Amvuttra |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $72.23 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.26 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $60.31 | 2019 | |
| Esperion Therapeutics, INC. | $46.80 | 2021-2022 | |
| Cvrx, INC. | $31.43 | 2021 | |
| Abiomed | $29.02 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $26.02 | 2019 | |
| Amarin Pharma, INC. | $21.43 | 2019 | |
| Kestra Medical Technology Services, INC. | $20.48 | 2022 | |
| Scpharmaceuticals INC. | $18.69 | 2024 | |
| Chiesi USA, INC. | $17.86 | 2025 | Kengreal |
| Bridgebio Pharma, INC. | $17.66 | 2025 | Attruby |
| Boston Scientific Corporation | $14.51 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.68 | 2020 | |
| Medtronic Vascular, INC. | $13.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Doughan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.